- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | PLRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 74.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REX | PLRX |
|---|---|---|
| Price | $50.13 | $1.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 127.7K | ★ 477.1K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.70 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $1.09 |
| 52 Week High | $64.95 | $1.95 |
Technical Indicators
Market Signals| Indicator | REX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 32.48 |
| Support Level | $49.75 | $1.10 |
| Resistance Level | $53.36 | $1.37 |
| Average True Range (ATR) | 1.68 | 0.04 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 51.06 | 7.14 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.